Updated safety and efficacy data from the phase 3 MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor treatment-na<spacing diaeresis>ive patients with myelofibrosis

被引：0

作者：

Rampal, Raajit

Grosicki, Sebastian

Chraniuk, Dominik

Abruzzese, Elisabetta

Bose, Prithviraj

Gerds, Aaron Thomas

Vannucchi, Alessandro M.

Palandri, Francesca

Lee, Sung-Eun

Gupta, Vikas

Lucchesi, Alessandro

Kuykendall, Andrew Tucker

Mesa, Ruben A.

Kiladjian, Jean-Jacques

Talpaz, Moshe

Harris, Morgan

Wu, Manlei

Brown, Barbara

Harrison, Claire

Mascarenhas, John

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, New York, NY USA

[2] Med Univ Silesia, Katowice, Poland

[3] Wojewodzki Szpital Zespolony L Rydygiera, Hematol Ward, Torun, Poland

[4] Tor Vergata Univ, Dept Hematol, S Eugenio Hosp, Rome, Italy

[5] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA

[6] Cleveland Clin, Taussig Canc Inst, Cleveland, OH USA

[7] Univ Florence, Dept Clin & Expt Med, Florence, Italy

[8] IRCCS Azienda Osped Univ Bologna, Ist Ematol S Orsola Malpighi, Bologna, Italy

[9] Catholic Univ Korea, Dept Hematol, Seoul St Marys Hosp, Coll Med, Seoul, South Korea

[10] Princess Margaret Canc Ctr, Med Oncol & Hematol, Toronto, ON, Canada

[11] IRCCS Ist Romagnolo & Cura Tumori IRST Dino Amado, Meldola, Italy

[12] Mofitt Canc Ctr, Tampa, FL USA

[13] Wake Forest Univ, Atrium Hlth Wake Forest Baptist Comprehens Canc C, Sch Med, Winston Salem, NC USA

[14] Univ Paris, Clin Invest Ctr, Hop St Louis, Paris, France

[15] Univ Michigan, Comprehens Canc Ctr, London, England

[16] Constellat Pharmaceut, Boston, MA USA

[17] MorphoSys US Inc, Boston, MA USA

[18] Guys & St Thomas NHS Fdn Trust, Dept Haematol, London, England

[19] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

6502

引用

页数：1

共 50 条

[1] Safety and Efficacy of Pelabresib in Combination With Ruxolitinib for JAK Inhibitor-Naive Patients With Myelofibrosis: Latest Data From the Phase 3 MANIFEST-2 Study
Mascarenhas, John
Rampal, Raajit K.
Grosicki, Sebastian
Chraniuk, Dominik
Abruzzese, Elisabetta
Bose, Prithviraj
Gerds, Aaron
Vannucchi, Alessandro M.
Palandri, Francesca
Lee, Sung-Eun
Gupta, Vikas
Lucchesi, Alessandro
Oh, Stephen T.
Kuykendall, Andrew T.
Patriarca, Andrea
Alvarez-Larran, Alberto
Mesa, Ruben
Kiladjian, Jean-Jacques
Talpaz, Moshe
Lavie, David
Harris, Morgan
Kays, Sarah-Katharina
Jegg, Anna Maria
Wu, Manlei
Brown, Barbara
Harrison, Claire
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S416 - S417
[2] Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor-Naive Patients with Myelofibrosis
Mascarenhas, John O.
Grosicki, Sebastian
Chraniuk, Dominik
Abruzzese, Elisabetta
Bose, Prithviraj
Gerds, Aaron T.
Vannucchi, Alessandro M.
Palandri, Francesca
Lee, Sung-Eun
Gupta, Vikas
Lucchesi, Alessandro
Oh, Stephen
Kuykendall, Andrew T.
Patriarca, Andrea
Alvarez-Larran, Alberto
Mesa, Ruben
Kiladjian, Jean-Jacques
Talpaz, Moshe
Harris, Morgan
Kays, Sarah-Katharina
Li, Qing
Brown, Barbara
Jegg, Anna-Maria
Harrison, Claire
Rampal, Raajit
BLOOD, 2024, 144 : 3178 - 3180
[3] Phase III MANIFEST-2: pelabresib plus ruxolitinib vs placebo plus ruxolitinib in JAK inhibitor treatment-naive myelofibrosis
Harrison, Claire N.
Gupta, Vikas K.
Gerds, Aaron T.
Rampal, Raajit
Verstovsek, Srdan
Talpaz, Moshe
Kiladjian, Jean-Jacques
Mesa, Ruben
Kuykendall, Andrew T.
Vannucchi, Alessandro M.
Palandri, Francesca
Grosicki, Sebastian
Devos, Timothy
Jourdan, Eric
Wondergem, Marielle J.
Al-Ali, Haifa Kathrin
Buxhofer-Ausch, Veronika
Alvarez-Larran, Alberto
Patriarca, Andrea
Kremyanskaya, Marina
Mead, Adam J.
Akhani, Sanjay
Sheikine, Yuri
Colak, Gozde
Mascarenhas, John
FUTURE ONCOLOGY, 2022, 18 (27) : 2987 - 2997
[4] Pelabresib Plus Ruxolitinib Combination Therapy in JAK Inhibitor-Naive Patients With Myelofibrosis in the Phase 3 MANIFEST-2 Study: Preliminary Evidence of Bone Marrow Recovery
Mascarenhas, John
Rampal, Raajit K.
Vannucchi, Alessandro M.
Gupta, Vikas
Oh, Stephen T.
Kuykendall, Andrew T.
Mesa, Ruben
Kiladjian, Jean-Jacques
Talpaz, Moshe
Kremyanskaya, Marina
Scandura, Joseph
Kraeft, Tabea
Eliane, Jean-Pierre
Chang, Tzuu-Wang
Cui, Jike
Kuffer, Christian
Boxhammer, Rainer
Harrison, Claire
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S417 - S418
[5] Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naive Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study
Rampal, Raajit K.
Grosicki, Sebastian
Chraniuk, Dominik
Abruzzese, Elisabetta
Bose, Prithviraj
Gerds, Aaron T.
Vannucchi, Alessandro M.
Palandri, Francesca
Lee, Sung-Eun
Gupta, Vikas
Lucchesi, Alessandro
Oh, Stephen T.
Kuykendall, Andrew T.
Patriarca, Andrea
Alvarez-Larran, Alberto
Mesa, Ruben
Kiladjian, Jean-Jacques
Talpaz, Moshe
Harris, Morgan
Kays, Sarah-Katharina
Jegg, Anna-Maria
Li, Qing
Brown, Barbara
Harrison, Claire N.
Mascarenhas, John
BLOOD, 2023, 142
[6] Clinical Benefit of Pelabresib (Cpi-0610) in Combination with Ruxolitinib in JAK Inhibitor Treatment-Naive Myelofibrosis Patients: Interim Efficacy Subgroup Analysis from Arm 3 of the MANIFEST Phase 2 Study
Gupta, Vikas
Kremyanskaya, Marina
Mascarenhas, John
Palandri, Francesca
Patriarca, Andrea
Devos, Timothy
Harrison, Claire
Passamonti, Francesco
Rampal, Raajit
Mead, Adam
Scandura, Joseph
Hobbs, Gabriela
Talpaz, Moshe
Granacher, Nikki
Somervaille, Tim
Hoffman, Ronald
Bose, Prithviraj
Colak, Gozde
Shao, James
Cui, Jike
Bobba, Suresh
Luptakova, Katarina
Verstovsek, Srdan
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S362 - S362
[7] Selinexor plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis: SENTRY Phase 3 study design
Mascarenhas, John
Maher, Keri
Rampal, Raajit
Bose, Prithviraj
Podoltsev, Nikolai
Hong, Junshik
Chai, Yi
Kye, Steve
Method, Michael
Harrison, Claire
FUTURE ONCOLOGY, 2025, 21 (07) : 807 - 813
[8] BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofibrosis - JAK Inhibitor-Naive or With Suboptimal Response to Ruxolitinib - Preliminary Data From the MANIFEST Study
Mascarenhas, John
Kremyanskaya, Marina
Patriarca, Andrea
Harrison, Claire
Bose, Prithviraj
Rampal, Raajit K.
Palandri, Francesca
Devos, Timothy
Passamonti, Francesco
Hobbs, Gabriela
Talpaz, Moshe
Vannucchi, Alessandro
Kiladjian, Jean-Jacques
Verstovsek, Srdan
Hoffman, Ron
Salama, Mohamed E.
Chen, Dong
Taverna, Pietro
Chang, Alex
Colak, Gozde
Klein, Sandra
Gupta, Vikas
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S335 - S336
[9] MANIFEST-2, A GLOBAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL STUDY OF CPI 0610 AND RUXOLITINIB VS. PLACEBO AND RUXOLITINIB IN JAK INHIBITOR-TREATMENT-NAIVE MYELOFIBROSIS PATIENTS
Passamonti, F.
Palandri, F.
Mascarenhas, J.
Harrison, C.
Patriarca, A.
Vannucchi, A.
Luptakova, K.
Wang, J.
Colak, G.
Shao, J.
Bobba, S.
Trojer, P.
Humphrey, J.
Verstovsek, S.
HAEMATOLOGICA, 2021, 106 (10) : 81 - 82
[10] MANIFEST-2, a Global, Phase 3, Randomized, Double-Blind, Active-Control Study of CPI-0610 and Ruxolitinib Vs. Placebo and Ruxolitinib in JAK-Inhibitor-Naive Myelofibrosis Patients
Mascarenhas, John
Harrison, Claire
Luptakova, Katarina
Christo, Jessica
Wang, Jing
Mertz, Jennifer A.
Colak, Gozde
Shao, James
Bobba, Suresh
Trojer, Patrick
Senderowicz, Adrian
Humphrey, Jeffrey S.
Verstovsek, Srdan
BLOOD, 2020, 136

← 1 2 3 4 5 →